Movement Alert｜REMEGEN Falls 5.1% in Regular Trading, Lock-Up Expiry Selling Pressure Compounded by Biotech Sector Pullback

Market Focus07-24

On July 24, REMEGEN fell 5.1% in regular trading, trading at HKD 82.95/share, with turnover of HKD 124 million.

On the news front, the company saw 193 million restricted shares unlocked on July 1, representing 34.16% of total share capital. Following this unlock, the company has no remaining restricted shares, and market absorption pressure continues to weigh on the stock. Although the company previously announced an A-share buyback plan of up to RMB 50 million for employee stock ownership or equity incentives, the dual headwinds of large-scale lock-up expiry selling and broad sector weakness have kept the stock under notable short-term pressure.

Within the Biotechnology sector, most peers traded lower. Among sector constituents, AKESO fell 3.7%, 3SBIO fell 2.11%, INNOVENT BIO fell 1.26%, SKB BIO fell 0.96%, while BEIGENE rose 2.48%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112807784?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 13:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112807784","market":"hk","top_or_hot":-1,"title":"Movement Alert｜REMEGEN Falls 5.1% in Regular Trading, Lock-Up Expiry Selling Pressure Compounded by Biotech Sector Pullback","media":"Market Focus","content":"<p><p>On July 24, REMEGEN fell 5.1% in regular trading, trading at HKD 82.95/share, with turnover of HKD 124 million.</p><p>On the news front, the company saw 193 million restricted shares unlocked on July 1, representing 34.16% of total share capital. Following this unlock, the company has no remaining restricted shares, and market absorption pressure continues to weigh on the stock. Although the company previously announced an A-share buyback plan of up to RMB 50 million for employee stock ownership or equity incentives, the dual headwinds of large-scale lock-up expiry selling and broad sector weakness have kept the stock under notable short-term pressure.</p><p>Within the Biotechnology sector, most peers traded lower. Among sector constituents, AKESO fell 3.7%, 3SBIO fell 2.11%, INNOVENT BIO fell 1.26%, SKB BIO fell 0.96%, while BEIGENE rose 2.48%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜REMEGEN Falls 5.1% in Regular Trading, Lock-Up Expiry Selling Pressure Compounded by Biotech Sector Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜REMEGEN Falls 5.1% in Regular Trading, Lock-Up Expiry Selling Pressure Compounded by Biotech Sector Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-24 13:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 24, REMEGEN fell 5.1% in regular trading, trading at HKD 82.95/share, with turnover of HKD 124 million.</p><p>On the news front, the company saw 193 million restricted shares unlocked on July 1, representing 34.16% of total share capital. Following this unlock, the company has no remaining restricted shares, and market absorption pressure continues to weigh on the stock. Although the company previously announced an A-share buyback plan of up to RMB 50 million for employee stock ownership or equity incentives, the dual headwinds of large-scale lock-up expiry selling and broad sector weakness have kept the stock under notable short-term pressure.</p><p>Within the Biotechnology sector, most peers traded lower. Among sector constituents, AKESO fell 3.7%, 3SBIO fell 2.11%, INNOVENT BIO fell 1.26%, SKB BIO fell 0.96%, while BEIGENE rose 2.48%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1112807784","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112807784","pubTimestamp":1784872458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, REMEGEN fell 5.1% in regular trading, trading at HKD 82.95/share, with turnover of HKD 124 million.On the news front, the company saw 193 million restricted shares unlocked on July 1,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"走势警报|REMEGEN 常规交易中下跌 5.1%，生物技术板块回调加剧了禁售到期抛售压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 24, REMEGEN fell 5.1% in regular trading, trading at HKD 82.95/share, with turnover of HKD 124 million.On the news front, the company saw 193 million restricted shares unlocked on July 1, representing 34.16% of total share capital. Following this unlock, the company has no remaining restricted shares, and market absorption pressure continues to weigh on the stock. Although the company previously announced an A-share buyback plan of up to RMB 50 million for employee stock ownership or equity incentives, the dual headwinds of large-scale lock-up expiry selling and broad sector weakness have kept the stock under notable short-term pressure.Within the Biotechnology sector, most peers traded lower. Among sector constituents, AKESO fell 3.7%, 3SBIO fell 2.11%, INNOVENT BIO fell 1.26%, SKB BIO fell 0.96%, while BEIGENE rose 2.48%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112807784","isCrawlerRequest":true}